Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 (Q37281824)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 July 2009

Language	Label	Description	Also known as
English	Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941	scientific article published on 07 July 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

24

object named as

Paul Workman

1 reference

Europe PubMed Central

19 August 2017

PMC publication ID

author name string

Florence I Raynaud

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Suzanne A Eccles

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sonal Patel

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sonia Alix

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Gary Box

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Irina Chuckowree

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Adrian Folkes

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sharon Gowan

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Alexis De Haven Brandon

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Francesca Di Stefano

10

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Angela Hayes

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Alan T Henley

12

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Letitia Lensun

13

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Giles Pergl-Wilson

14

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Anthony Robson

15

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Nahid Saghir

16

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Alexander Zhyvoloup

17

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Edward McDonald

18

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Peter Sheldrake

19

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Stephen Shuttleworth

20

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Melanie Valenti

21

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Nan Chi Wan

22

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Paul A Clarke

23

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

7 July 2009

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1725-1738

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

PI3K pathway alterations in cancer: variations on a theme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Class I PI3K in oncogenic cellular transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

AKT signaling in regulating angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Pharmacodynamic biomarkers for molecular cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Oncogenic PI3K deregulates transcription and translation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

High frequency of mutations of the PIK3CA gene in human cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Phosphoinositide 3-kinase signalling--which way to target?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

The phosphoinositide 3-kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Role of the PI3K regulatory subunit in the control of actin organization and cell migration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Signaling by distinct classes of phosphoinositide 3-kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

The role of phosphoinositide 3-kinase lipid products in cell function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Phosphoinositide 3-kinases: a conserved family of signal transducers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

6 September 2017

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

14 September 2017

PI3K: downstream AKTion blocks apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

28 September 2017

Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

26 June 2018

Inhibiting PI-3-K for glioma therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

The PI3K inhibitor arsenal: choose your weapon!

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

Structure and function of phosphoinositide 3-kinases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2718129

3 September 2018

Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19584227

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19584227

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1535-7163.MCT-08-1200

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37281824&oldid=2240694377"